Scholar Rock Presents Data for SRK-015 at the SMA Europe 2nd International Scientific Congress
February 06, 2020 07:53 ET
|
Scholar Rock
CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
January 09, 2020 07:30 ET
|
Scholar Rock
Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients...
Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy
November 19, 2019 07:30 ET
|
Scholar Rock
Biomarker results confirm presence of latent myostatin in patients with SMA, further supporting relevance of drug target in diseaseSRK-015 demonstrated robust and dose-dependent target engagementData...
Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress
October 02, 2019 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise
September 05, 2019 07:30 ET
|
Scholar Rock
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference
August 07, 2019 16:01 ET
|
Scholar Rock
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
June 19, 2019 07:30 ET
|
Scholar Rock
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
June 03, 2019 16:05 ET
|
Scholar Rock
- SRK-015 was well-tolerated in healthy volunteers across all tested doses, supporting evaluation in the ongoing Phase 2 TOPAZ trial in Spinal Muscular Atrophy (SMA) - Pharmacodynamic results...
Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference
May 28, 2019 16:05 ET
|
Scholar Rock
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
May 08, 2019 16:05 ET
|
Scholar Rock
Dosing of patients has commenced in TOPAZ, the Phase 2 clinical trial of SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA)Preliminary PK/PD data from a subset of patients are anticipated by...